Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

BACKGROUND: Widely established targeted therapies directed at triple negative breast cancer (TNBC) are missing. Classical chemotherapy remains the systemic treatment option. Cisplatin has been tested in TNBC but bears the disadvantage of resistance development. The purpose of this study was to ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohr, Katharina, Hamacher, Alexandra, Engelke, Laura H., Kassack, Matthias U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670521/
https://www.ncbi.nlm.nih.gov/pubmed/29100507
http://dx.doi.org/10.1186/s12885-017-3695-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670521/
https://www.ncbi.nlm.nih.gov/pubmed/29100507
http://dx.doi.org/10.1186/s12885-017-3695-5

Ejemplares similares